Early application of low‑dose glucocorticoid improves acute respiratory distress syndrome: A meta‑analysis of randomized controlled trials

Yang,Zhi‑Gang; Lei,Xiao‑Li; Li,Xiao‑Liang

doi:10.3892/etm.2017.4154

Early application of low‑dose glucocorticoid improves acute respiratory distress syndrome: A meta‑analysis of randomized controlled trials

Authors:
- Zhi‑Gang Yang
- Xiao‑Li Lei
- Xiao‑Liang Li
View Affiliations

Affiliations: Department of Respiratory Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China
Published online on: February 22, 2017 https://doi.org/10.3892/etm.2017.4154
Pages: 1215-1224
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous clinical trials have investigated the effect of glucocorticoid therapy in acute respiratory distress syndrome (ARDS), with controversial results, particularly with regard to the early administration of low dose glucocorticoid. The present meta‑analysis aimed to assess whether the application of glucocorticoid was able to reduce mortality in patients with ARDS. A literature search was performed using online databases, including MEDLINE, Embase, Cochrane and CNKI regardless of whether the studies were published in English or Chinese. Following assessment via inclusion and exclusion criteria, two reviewers screened controlled randomized trials which investigated glucocorticoid therapy in ARDS patients and independently extracted data. The quality of all of the included trials was evaluated based on blinding, randomization and other methods. A total of 14 studies with 1,441 patients met the inclusion criteria. The results of the meta‑analysis demonstrated that glucocorticoid significantly reduced the overall mortality of patients with ARDS [relative ratio (RR), 0.68; 95% confidence interval (CI), 0.50‑0.91; P<0.05], particularly with a low‑dose of glucocorticoid (RR, 0.57; 95% CI, 0.39‑0.84; P<0.05) at the early phase of ARDS (RR, 0.37; 95% CI, 0.16‑0.86; P<0.05), and a longer duration of steroids (RR, 0.44; 95% CI, 0.30‑0.64; P<0.05). Administration of steroids also significantly increased the number of days that patients remained alive and were off mechanical ventilation (RR, 3.08; 95% CI, 1.49‑4.68; P<0.05) without significantly increasing the novel infection rate (RR, 1.00; 95% CI, 0.44‑2.25; P<0.05). Due to inconsistencies and other limitations, the quality of the studies used for the meta‑analysis of the effect of glucocorticoid on mortality was low. In conclusion, early use of low dose glucocorticoid may effectively reduce mortality in patients with ARDS. However, this conclusion may be affected by the limited quality of the studies included in the present meta‑analysis.

View Figures

View References

1	Koh Y: Update in acute respiratory distress syndrome. J Intensive Care. 2:22014. View Article : Google Scholar : PubMed/NCBI
2	Del Sorbo L and Slutsky AS: Acute respiratory distress syndrome and multiple organ failure. Curr Opin Crit Care. 17:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
3	Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, et al PROSEVA Study Group, : Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 368:2159–2168. 2013. View Article : Google Scholar : PubMed/NCBI
4	Mondrinos MJ, Kennedy PA, Lyons M, Deutschman CS and Kilpatrick LE: Protein kinase C and acute respiratory distress syndrome. Shock. 39:467–479. 2013. View Article : Google Scholar : PubMed/NCBI
5	Carnesecchi S, Pache JC and Barazzone-Argiroffo C: NOX enzymes: Potential target for the treatment of acute lung injury. Cell Mol Life Sci. 69:2373–2385. 2012. View Article : Google Scholar : PubMed/NCBI
6	Carnesecchi S, Dunand-Sauthier I, Zanetti F, Singovski G, Deffert C, Donati Y, Cagarelli T, Pache JC, Krause KH, Reith W and Barazzone-Argiroffo C: NOX1 is responsible for cell death through STAT3 activation in hyperoxia and is associated with the pathogenesis of acute respiratory distress syndrome. Int J Clin Exp Pathol. 7:537-551.eCollection 20142014.
7	Meduri G, Bell W, Sinclair S and Annane D: Pathophysiology of acute respiratory distress syndrome. Glucocorticoid receptor-mediated regulation of inflammation and response to prolonged glucocorticoid treatment. Presse Med. 40:e543-e5602011.
8	Vandevyver S, Dejager L, Tuckermann J and Libert C: New insights into the anti-inflammatory mechanisms of glucocorticoids: An emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 154:993–1007. 2013. View Article : Google Scholar : PubMed/NCBI
9	Nixon M, Andrew R and Chapman KE: It takes two to tango: Dimerisation of glucocorticoid receptor and its anti-inflammatory functions. Steroids. 78:59–68. 2013. View Article : Google Scholar : PubMed/NCBI
10	Headley AS, Tolley E and Meduri GU: Infections and the inflammatory response in acute respiratory distress syndrome. Chest. 111:1306–1321. 1997. View Article : Google Scholar : PubMed/NCBI
11	Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R and Leeper K: Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 107:1062–1073. 1995. View Article : Google Scholar : PubMed/NCBI
12	Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N and Meade M: Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome and severe pneumonia: A meta-analysis of randomized controlled trials. J Crit Care. 25:420–435. 2010. View Article : Google Scholar : PubMed/NCBI
13	Rocco PR, Souza AB, Faffe DS, Pássaro CP, Santos FB, Negri EM, Lima JG, Contador RS, Capelozzi VL and Zin WA: Effect of corticosteroid on lung parenchyma remodeling at an early phase of acute lung injury. Am J Respir Crit Care Med. 168:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
14	Confalonieri M, Annane D, Antonaglia C, Santagiuliana M, Borriello EM and Meduri GU: Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia? Curr Infect Dis Rep. 15:158–166. 2013. View Article : Google Scholar : PubMed/NCBI
15	Matthay MA, Song Y, Bai C and Jones KD: The acute respiratory distress syndrome in 2013. Translational Respiratory Medicine. 1:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
16	Thompson BT: Corticosteroids for ARDS. Minerva Anestesiol. 76:441–447. 2010.PubMed/NCBI
17	Wajanaponsan N, Reade MC and Milbrandt EB: Steroids in late ARDS? Crit Care. 11:3102007. View Article : Google Scholar : PubMed/NCBI
18	Hwangbo B, Lee HS, Lee JM, Kim MS, Kim HY, Choi YJ and Zo JI: Low dose steroid therapy at an early phase of acute respiratory distress syndrome after thoracic surgery. Chest Journal. 126:719S-a-719S2004. View Article : Google Scholar
19	Fremont RD and Rice T: Low-dose steroids in ARDS. Chest. 132:10952007. View Article : Google Scholar : PubMed/NCBI
20	Peter JV, John P, Graham PL, Moran JL, George IA and Bersten A: Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: Meta-analysis. BMJ. 336:1006–1009. 2008. View Article : Google Scholar : PubMed/NCBI
21	Higgins J and Altman DG: Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell; Chichester: pp. 187–241. 2008, View Article : Google Scholar
22	Weigelt JA, Norcross JF, Borman KR and Snyder WH III: Early steroid therapy for respiratory failure. Arch Surg. 120:536–540. 1985. View Article : Google Scholar : PubMed/NCBI
23	Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA, et al: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 317:1565–1570. 1987. View Article : Google Scholar : PubMed/NCBI
24	Marik P, Kraus P, Sribante J, Havlik I, Lipman J and Johnson DW: Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 104:389–392. 1993. View Article : Google Scholar : PubMed/NCBI
25	Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Porta R Della, Giorgio C, Blasi F, Umberger R and Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med. 171:242–248. 2005. View Article : Google Scholar : PubMed/NCBI
26	Annane D, Sébille V and Bellissant E; Ger-Inf-05 Study Group, : Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 34:22–30. 2006. View Article : Google Scholar : PubMed/NCBI
27	Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT and Ancukiewicz M: National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 354:1671–1684. 2006. View Article : Google Scholar : PubMed/NCBI
28	Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M and Umberger R: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 131:954–963. 2007. View Article : Google Scholar : PubMed/NCBI
29	Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, Narumoto O, Kichikawa Y, Kawai M, Tashimo H, Arai H, Horiuchi T and Sakamoto Y: Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 185:249–255. 2007. View Article : Google Scholar : PubMed/NCBI
30	Wan MH, Li J, Gong HL, Xue P, Zhu L, Chen GY, Xia Q and Wen-Fu T: Clinical observation on the effect of dexamethasone and Chinese herbal decoction for purgation in severe acute pancreatitis patients. Chin J Integr Med. 17:141–145. 2011. View Article : Google Scholar : PubMed/NCBI
31	Ferguson N, Adhikari N, Cook D, Hand L, Henzler D, Zhou Q, Meade M and Lamontagne F: Corticosteroid use in ARDS patients enrolled in the oscillation for ARDS treated early (oscillate) trial. Am J Respir Crit Care Med. 183:A11692011.
32	Azevedo AF, Miranda-Filho DB, Henriques-Filho GT, Leite A and Ximenes RA: Randomized controlled trial of pulse methyl prednisolonex placebo in treatment of pulmonary involvement associated with severe leptospirosis. [ISRCTN74625030]. BMC Infect Dis. 11:1862011. View Article : Google Scholar : PubMed/NCBI
33	Seam N, Meduri GU, Wang H, Nylen ES, Sun J, Schultz MJ, Tropea M and Suffredini AF: Effects of methylprednisolone infusion on markers of inflammation, coagulation and angiogenesis in early acute respiratory distress syndrome. Crit Care Med. 40:495–501. 2012. View Article : Google Scholar : PubMed/NCBI
34	Liu L, Li J, Huang YZ, Liu SQ, Yang CS, Guo FM, Qiu HB and Yang Y: The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency. Zhonghua Nei Ke Za Zhi. 51:599–603. 2012.(In Chinese). PubMed/NCBI
35	Thompson BT: Glucocorticoids and acute lung injury. Crit Care Med. 31 Suppl 4:S253–S257. 2003. View Article : Google Scholar : PubMed/NCBI
36	Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M and Umberger R: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest. 131:954–963. 2007. View Article : Google Scholar : PubMed/NCBI
37	Suter PM: Lung inflammation in ARDS - friend or foe? N Engl J Med. 354:1739–1742. 2006. View Article : Google Scholar : PubMed/NCBI
38	Annane D: Glucocorticoids for ARDS: Just do it! Chest. 131:945–946. 2007. View Article : Google Scholar : PubMed/NCBI